Mercados españoles cerrados

Axonics, Inc. (AXNX)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
67,55-0,12 (-0,18%)
Al cierre: 04:00PM EDT
67,12 -0,43 (-0,64%)
Después del cierre: 04:06PM EDT

Axonics, Inc.

26 Technology Drive
Irvine, CA 92618
United States
949 396 6322
https://www.axonics.com

Sector(es)Healthcare
SectorMedical Devices
Empleados a tiempo completo797

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Raymond W. CohenCEO & Director1,75MN/A1959
Ms. Kari KeeseChief Financial Officer1,64M46,74k1985
Mr. Rinda K. SamaChief Operating Officer888,2kN/A1979
Dr. John Woock Ph.D.Executive VP, Chief Marketing & Strategy Officer888,2k1,51M1983
Mr. Alfred J. Ford Jr.Chief Commercial Officer909,52k1,9M1971
Mr. Guangqiang Jiang Ph.D.Chief Technology OfficerN/AN/A1974
Mr. Neil BhalodkarVice President of Investor RelationsN/AN/AN/A
Mr. Aaron PettitGeneral Counsel & Chief Compliance OfficerN/AN/AN/A
Mr. Michael V. Williamson Esq., J.D.Senior VP, General & IP CounselN/AN/A1972
Dr. Karen L. Noblett M.A.S., M.D.Chief Medical Officer651,4k897,47k1963
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Gobierno corporativo

El ISS Governance QualityScore de Axonics, Inc., a día 1 de mayo de 2024, es 5. Las puntuaciones base son Auditoría: 10; Tablero: 3; Derechos de los accionistas: 4; Compensación: 3.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.